Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NY-ESO-1 T Cells and LV305 in Sarcoma
NCT03450122Phase 1Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 2018
- Primary completion
- Dec 2022
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines, mRNA Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of autologous NY-ESO-1-specific CD8-positive T lymphocytes and LV305 in synovial sarcoma (SS) and myxoid liposarcoma (MLPS) (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Duration of in vivo persistence of transferred T cells up to 168 days, The nature, frequency and severity of adverse events up to 168 days and 1 more. Started Sep 2018; status: completed.
02
Drugs
autologous NY-ESO-1-specific CD8-positive T lymphocytesLV305
03
Conditions
synovial sarcoma (SS)myxoid liposarcoma (MLPS)
Beyond the preview
Go deeper on NCT03450122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03450122.